Molecular diagnostics of a single drug-resistant multiple myeloma case using targeted next-generation sequencing

: A 69-year-old man was diagnosed with IgG λ -type multiple myeloma (MM), Stage II in October 2010. He was treated with one cycle of high-dose dexamethasone. After three cycles of bortezomib, the patient exhibited slow elevations in the free light-chain levels and developed a significant new increase of serum M protein. Bone marrow cytogenetic analysis revealed a complex karyotype characteristic of malignant plasma cells. To better understand the molecular pathogenesis of this patient, we sequenced for mutations in the entire coding regions of 409 cancer-related genes using a semiconductor-based sequencing platform. Sequencing analysis revealed eight nonsynonymous somatic mutations in addition to several copy number variants, including CCND1 and RB1. These alterations may play roles in the pathobiology of this disease. This targeted next-generation sequencing can allow for the prediction of drug resistance and facilitate improvements in the treatment of MM patients.

[1]  M. Taniwaki,et al.  Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma. , 2014, Cancer research.

[2]  S. Fatakia,et al.  Ion Torrent sequencing for conducting genome-wide scans for mutation mapping analysis , 2014, Mammalian Genome.

[3]  R. Fonseca,et al.  Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution. , 2013, Clinical lymphoma, myeloma & leukemia.

[4]  A. Zannettino,et al.  Circulating N‐cadherin levels are a negative prognostic indicator in patients with multiple myeloma , 2013, British journal of haematology.

[5]  K. Anderson.  Therapeutic advances in relapsed or refractory multiple myeloma. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  A Rosenwald,et al.  Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules , 2013, Blood Cancer Journal.

[7]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[8]  N. Munshi,et al.  Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. , 2009, Blood.

[9]  Jeffrey Ecsedy,et al.  A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. , 2009, Blood.

[10]  K. Anderson,et al.  The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo , 2009, Clinical Cancer Research.

[11]  KyungMann Kim,et al.  Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells , 2008, Molecular Cancer Research.

[12]  Darryl Shibata,et al.  Unregulated smooth-muscle myosin in human intestinal neoplasia , 2008, Proceedings of the National Academy of Sciences.

[13]  S. Baylin,et al.  Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. , 2008, Cancer research.

[14]  K. Anderson,et al.  Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells , 2007, British journal of haematology.

[15]  Wei Chen,et al.  Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer , 2007, PLoS genetics.

[16]  Yulia Nefedova,et al.  Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. , 2004, Blood.

[17]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[18]  Lisa Garrett,et al.  The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia , 1999, Nature Genetics.

[19]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.